Table 3 CYP2A6 genotypes, cigarette smoking and risk of lung cancer in the studied Egyptian population
| Â | CYP2A6 | ||
|---|---|---|---|
CYP2A6*1 (AA) | CYP2A6*9 (AC) | CYP2A6*2 (AT) | |
Control/ cancer n | 144/143 | 5/6 | 1/1 |
OR (95% C.I.) | 1.2 (0.36–4.02) | 0.8 (0.2–2.8) | 0.99 (0.1–16) |
P value | P = 0.77 | P = 0.77 | P = 0.99 |
Non-Smoker | |||
 Control/ cancer n | 114/52 | 5/4 | 1/1 |
 OR (95% C.I.) | 1.7 (0.4–6.7) | 0.6 (0.1–2.2) | 2.1 (0.1–34.6) |
 P value | P = 0.42 | P = 0.42 | P = 0.60 |
Smoker | |||
 Control/ cancer n | 30/91 | 0/2 | (a) |
 OR (95% C.I.) | 1.0 (0.99–1.1) | 1.0 (1.0–1.1) | |
 P value | P = 0.30 | P = 0.30 | |
Pack-year < 20 | |||
 Control/ cancer n | 16/37 |  |  |
 OR (95% C.I.) | (a) | (a) | (a) |
 P value |  |  |  |
Pack-year ≥20 | |||
 Control/ cancer n | 14/54 | 0/2 | (a) |
 OR (95% C.I.) | 1.0 (0.99–1.09) | 1.0 (0.99–1.1) | |
 P value | P = 0.36 | P = 0.36 | |